CO2024000517A2 - Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva - Google Patents
Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitivaInfo
- Publication number
- CO2024000517A2 CO2024000517A2 CONC2024/0000517A CO2024000517A CO2024000517A2 CO 2024000517 A2 CO2024000517 A2 CO 2024000517A2 CO 2024000517 A CO2024000517 A CO 2024000517A CO 2024000517 A2 CO2024000517 A2 CO 2024000517A2
- Authority
- CO
- Colombia
- Prior art keywords
- atp
- methods
- cognitive function
- compositions containing
- adenosine triphosphate
- Prior art date
Links
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 title 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 2
- 229960001456 adenosine triphosphate Drugs 0.000 abstract 2
- 230000036997 mental performance Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Se proporcionan métodos de uso y composiciones que comprenden una fuente de adenosín 5’-trifosfato (ATP). La administración de las composiciones descritas mejora la función cognitiva, los tiempos de reacción, la concentración, el estado de ánimo, la reactividad neuromuscular y/u optimiza el rendimiento mental.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213378P | 2021-06-22 | 2021-06-22 | |
| PCT/US2022/034510 WO2022271813A1 (en) | 2021-06-22 | 2022-06-22 | Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000517A2 true CO2024000517A2 (es) | 2024-05-10 |
Family
ID=84544774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000517A CO2024000517A2 (es) | 2021-06-22 | 2024-01-22 | Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240299435A1 (es) |
| EP (1) | EP4358972A1 (es) |
| JP (1) | JP2024524288A (es) |
| CN (1) | CN117835985A (es) |
| AU (1) | AU2022297444A1 (es) |
| CA (1) | CA3224861A1 (es) |
| CL (1) | CL2023003882A1 (es) |
| CO (1) | CO2024000517A2 (es) |
| EC (1) | ECSP24004256A (es) |
| MX (1) | MX2024000145A (es) |
| WO (1) | WO2022271813A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
| EP3278800B1 (en) * | 2010-12-23 | 2019-04-10 | Amazentis SA | Compositions and methods for improving mitochondrial function and treating muscle-related pathological conditions |
| AU2014204233B2 (en) * | 2013-01-03 | 2018-11-08 | Laila Nutraceuticals | Synergistic dietary supplement for enhancing physical performance |
-
2022
- 2022-06-22 US US18/573,609 patent/US20240299435A1/en active Pending
- 2022-06-22 CN CN202280056829.6A patent/CN117835985A/zh active Pending
- 2022-06-22 AU AU2022297444A patent/AU2022297444A1/en active Pending
- 2022-06-22 CA CA3224861A patent/CA3224861A1/en active Pending
- 2022-06-22 WO PCT/US2022/034510 patent/WO2022271813A1/en active Application Filing
- 2022-06-22 MX MX2024000145A patent/MX2024000145A/es unknown
- 2022-06-22 EP EP22829221.5A patent/EP4358972A1/en active Pending
- 2022-06-22 JP JP2023579443A patent/JP2024524288A/ja active Pending
-
2023
- 2023-12-22 CL CL2023003882A patent/CL2023003882A1/es unknown
-
2024
- 2024-01-19 EC ECSENADI20244256A patent/ECSP24004256A/es unknown
- 2024-01-22 CO CONC2024/0000517A patent/CO2024000517A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117835985A (zh) | 2024-04-05 |
| CA3224861A1 (en) | 2022-12-29 |
| JP2024524288A (ja) | 2024-07-05 |
| US20240299435A1 (en) | 2024-09-12 |
| EP4358972A1 (en) | 2024-05-01 |
| CL2023003882A1 (es) | 2024-07-05 |
| WO2022271813A1 (en) | 2022-12-29 |
| MX2024000145A (es) | 2024-03-22 |
| AU2022297444A1 (en) | 2024-01-18 |
| ECSP24004256A (es) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8402A (es) | Indazol-o-glucosidos sustitutos | |
| GT201000061A (es) | Derivados de uracilo o timina para el tratamiento de hepatitis c | |
| MX9305769A (es) | Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| ES2058185T3 (es) | Derivados de camptotecina y procedimiento para su preparacion. | |
| UY28679A1 (es) | Nuevos derivados organofosforados de los indazoles y utilización como médicamentos. | |
| ES2039269T5 (es) | Derivados de azolilmetil-ciclopropilo. | |
| ECSP034830A (es) | Derivados sustituidos de la ciclohexano-1,4- diamina | |
| ECSP055609A (es) | "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor" | |
| ES2076688T3 (es) | Derivados de 2-hidroxi-2-feniletilamina utiles como agonistas de beta-3-adrenoceptores. | |
| SV2004001690A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| ES2052881T3 (es) | Agentes reductores de la presion sanguinea. | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| PA8608901A1 (es) | Derivados de piperazina | |
| KR920021148A (ko) | 항바이러스 조성물 | |
| AR062425A1 (es) | Formulacion de aerosol para la inhalacion de agonistas beta | |
| UY26370A1 (es) | "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación". | |
| UY38809A (es) | Derivados de 3,6-diamino-piridazin-3ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
| ES2067874T3 (es) | Derivados de acetamida. | |
| CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO2023014622A2 (es) | Conjugados de anticuerpo-fármaco anti-c-met | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| CL2004000979A1 (es) | Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida. | |
| BRPI0814725B8 (pt) | uso da composição antiviral | |
| CO2024000517A2 (es) | Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva | |
| AR045114A1 (es) | Suspension concentrada en aceite conteniendo diflufenican |